Skip to main content

Technology

Recursion: Pioneering TechBio Solutions in Drug Discovery

Published

Dec 17, 2024

About this Series

Live From MarketSite

With Kristina Ayanian

Nasdaq Listings Host Kristina Ayanian delves into companies' notable accomplishments, industry trends, and the driving factors behind their success through engaging conversations with C-suite executives and industry leaders.

Najat Khan, Chief R&D Officer and Chief Commercial Officer, and David Hallett, Chief Scientific Officer at Recursion sit down with Nasdaq's Kristina Ayanian to discuss the strategic advantage of the EXAI and Recursion merger and trends that investors should be looking at moving forward.

No transcript available

More in this Series

See all

My Quotes
My European Quotes
Watchlist
Portfolio

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ETFs and more asset classes.

/

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Shares, Indexes, ETP and more asset classes.

/

Edit Watchlist

Your Watchlist is empty.

Create your Watchlist to save your favorite quotes on Nasdaq.com. Log in or create a free account to get started.

/

Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Go to Smart Portfolio